Dermata Therapeutics (DRMA) Institutional Ownership $1.08 +0.03 (+2.86%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Dermata Therapeutics (NASDAQ:DRMA)CurrentInstitutional OwnershipPercentage8.67%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$2.06MNumber ofInstitutional Sellers(last 12 months)0 Get DRMA Insider Trade Alerts Want to know when executives and insiders are buying or selling Dermata Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data DRMA Institutional Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Dermata Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024 Armistice Capital LLC28,000$67K0.0%N/A4.982% 2/13/2024 Armistice Capital LLC218,000$133K0.0%N/A6.158% 11/13/2023 Acadian Asset Management LLC75,538$79K0.0%+34.2%2.368% 8/7/2023 Acadian Asset Management LLC56,285$92K0.0%N/A2.405% 7/27/2023 Virtu Financial LLC32,105$53K0.0%N/A1.372% 11/7/2022 Virtu Financial LLC70,808$37K0.0%N/A0.701% (Data available from 1/1/2016 forward) DRMA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of DRMA shares? During the previous two years, the following institutional investors and hedge funds held shares of Dermata Therapeutics shares: Acadian Asset Management LLC ($79K), and Armistice Capital LLC ($67K), Virtu Financial LLC ($53K).Learn more on DRMA's institutional investors. What percentage of Dermata Therapeutics stock is owned by institutional investors? 8.67% of Dermata Therapeutics stock is owned by institutional investors. Learn more on DRMA's institutional investor holdings. Which institutional investors have been buying Dermata Therapeutics stock? The following institutional investors have purchased Dermata Therapeutics stock in the last 24 months: Armistice Capital LLC ($246K), Acadian Asset Management LLC ($75.54K), and Virtu Financial LLC ($32.11K). How much institutional buying is happening at Dermata Therapeutics? Institutional investors have bought a total of 353,643 shares in the last 24 months. This purchase volume represents approximately $4.56M in transactions. Related Companies GNPX Institutional Ownership BCLI Institutional Ownership ENSC Institutional Ownership BFRI Institutional Ownership AYTU Institutional Ownership ADXN Institutional Ownership VIRX Institutional Ownership SNGX Institutional Ownership COEP Institutional Ownership NLSP Institutional Ownership This page (NASDAQ:DRMA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
